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Abstract
Background: The objective of this study was to evaluate the performance of risk scores (Framingham, Assign and QRISK2) in
predicting high cardiovascular disease (CVD) risk in individuals rather than populations.
Methods and findings: This study included 1.8 million persons without CVD and prior statin prescribing using the Clinical
Practice Research Datalink. This contains electronic medical records of the general population registered with a UK general
practice. Individual CVD risks were estimated using competing risk regression models. Individual differences in the 10-year
CVD risks as predicted by risk scores and competing risk models were estimated; the population was divided into 20
subgroups based on predicted risk. CVD outcomes occurred in 69,870 persons. In the subgroup with lowest risks, risk
predictions by QRISK2 were similar to individual risks predicted using our competing risk model (99.9% of people had
differences of less than 2%); in the subgroup with highest risks, risk predictions varied greatly (only 13.3% of people had
differences of less than 2%). Larger deviations between QRISK2 and our individual predicted risks occurred with calendar
year, different ethnicities, diabetes mellitus and number of records for medical events in the electronic health records in the
year before the index date. A QRISK2 estimate of low 10-year CVD risk (,15%) was confirmed by Framingham, ASSIGN and
our individual predicted risks in 89.8% while an estimate of high 10-year CVD risk ($20%) was confirmed in only 48.6% of
people. The majority of cases occurred in people who had predicted 10-year CVD risk of less than 20%.
Conclusions: Application of existing CVD risk scores may result in considerable misclassification of high risk status. Current
practice to use a constant threshold level for intervention for all patients, together with the use of different scoring
methods, may inadvertently create an arbitrary classification of high CVD risk.
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Introduction
Cardiovascular disease (CVD) is a major cause of mortality and
morbidity worldwide. It causes impaired quality of life and
accounts for a large share of health services utilization [1]. Statins
are widely used medications in the prevention of CVD. A recent
Cochrane review reported that statins reduce the risk of mortality
by 16% and CVD outcomes by 26% in people without a history of
CVD [1]. Most guidelines recommend that statins should only be
used in primary prevention in people with a high absolute CVD
risk [2,3]. As an example, the National Collaborating Centre for
Primary Care and Royal College of General Practitioners and the
National Institute of Clinical Excellence (NICE) recommended in
2007 to use statins ‘‘…as part of the management strategy for the
primary prevention of CVD for adults who have a 20% or greater
10-year CVD risk of developing CVD…’’ [2].
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A large number of risk assessment tools have been developed to
support clinicians in determining the long-term risks of CVD [4].
The Framingham, ASSIGN and QRISK2 risk scores are widely
used to predict 10-year CVD risk for primary prevention. The
Framingham risk score is based on a US cohort recruited several
decades ago [5]. The ASSIGN risk score was derived from the
Scottish Heart Health Extended Cohort [6] and the QRISK risk
score from a large primary care database in England and Wales
[7,8]. These scores were based on risk factors that can easily be
measured in the general population. The Framingham, ASSIGN
and QRISK2 risk scores have been validated by comparing
observed to predicted risks in the overall population [9]. There is
no consensus about what risk score to use for CVD risk assessment
and guidelines for primary CVD prevention propose to use any
risk score [10]. These three risk scores are currently being used in
the UK to determine CVD risk.
A recent review of CVD risk prediction models recommended
that claims of improved performance of new models over
established models should be documented in several studies
carried out by independent investigators [9]. There is little
evidence about how accurately these risk scores predict high CVD
risk in individuals. A risk score could perform well in the overall
population if it consistently predicts low rather than high risks as
those at high risks are typically only a minority [11]. The objective
of this study was to evaluate the validity and reliability of the
Framingham, ASSIGN and QRISK2 scores in predicting
individual CVD risk.
Material and Methods
Data source
This study used data from the General Practice Research
Database in the United Kingdom which is part of the Clinical
Practice Research Datalink (CPRD), previously known as the
General Practice Research Database. CPRD comprises the
computerised medical records maintained by general practitioners
(GPs). Almost all people in the UK are registered with a general
practice. GPs play a key role in the UK health care system, as they
are responsible for primary health care and specialist referrals.
The GPs are typically informed by hospitals of diagnoses made
during outpatient consultations and hospitalisations. The data
recorded in the CPRD since 1987 include demographic informa-
tion, prescription details, clinical events, preventive care provided,
specialist referrals, hospital admissions and their major outcomes
[12]. A recent review of validation studies found that medical data
in the CPRD were generally of high quality [13]. Fifty-five studies
of the CPRD recording of diseases of the circulatory system
reported a median percentage of cases confirmed of 85.3% [13].
People in CPRD have now been linked individually and
anonymously to the national registry of hospital admission
(Hospital Episode Statistics [HES]) and death certificates. The
linkages are performed using the patient’s unique NHS number,
date of birth, sex and postcode of residence. HES collect the dates
of hospital admission and discharge and main diagnoses, as
extracted from the medical records by coding staff in England.
The death certificates list the date and causes of death. Linked
data were available for 50% of the CPRD population as, at the
time of the study, this only included practices in England willing to
provide unique patient identifiers to the Trusted Third Party. The
protocol of this study was approved by the CPRD Independent
Scientific Advisory Committee.
Study populations
The main study population consisted of people aged 35–74
years, using the November 2011 version of CPRD and drawn
from CPRD practices that participated in the linkages. The start of
follow-up was one year after start of the patient’s CPRD data
collection or 1 January 1998, whichever date came last. HES and
death certificates data were available from 1998 onwards. The end
of follow-up was the patient’s end of CPRD data collection or
death. The index date at which the CVD risk assessment was
conducted, was a randomly selected date during this period of
follow-up. This approach was different from that used in the
QRISK2 analysis, which set the index date to 1-1-1998 unless the
patient’s data collection started later (e.g. due to patient newly
registering). The use of a random index date was preferred in
order to investigate changes in data recording (a newly registered
patient may have different levels of e.g. missing data). The
following persons were excluded: (i) those with CVD prior to the
index date or with missing dates, (ii) those prescribed a statin prior
to the index date or with missing dates, (iii) those temporarily
registered with the practice. Follow-up was censored at the date of
a first statin prescription.
Outcomes
The following incident CVD outcomes were included:
(i) CVD as recorded by the GPs (myocardial infarction, angina,
coronary heart disease, stroke and transient ischemic attack).
(ii) hospitalisation due to CVD as recorded by the hospital in
HES (either primary or secondary admission diagnostic
ICD10 codes): angina pectoris (I20); acute myocardial
infarction (I21); complications following acute myocardial
infarction (I23); other acute ischaemic heart disease (I24);
chronic ischaemic heart disease (I25); cerebral infarction
(I63); and stroke, not specified as haemorrhage or infarction
(I64), as used for QRISK2 [8]. Additional codes included
intracerebral haemorrhage (I61) and other nontraumatic
intracranial haemorrhage (I62).
(iii) Death due to CVD as reported on a death certificate
(primary or secondary cause). The ICD-10 codes were
similar to those used for hospitalisations.
Death due to causes other than CVD was also measured.
Imputation for missing variables
Missing values for smoking status, systolic blood pressure, ratio
of total serum cholesterol and high density lipoprotein (HDL)
cholesterol and BMI were imputed (using MI and MIANALYZE
imputation procedures in SAS). The imputation regression models
included the risk factors as listed in supplementary Table 1, CVD
occurrence, death due to causes other than CVD, duration of
follow-up and interactions between CVD occurrence and death
and duration of follow-up. Five imputation datasets were created
and the effect estimates were based on the combination of point
and variance estimates from these five datasets [14]. The same
imputed values for each patient were used across the different risk
scores.
CVD risk scores
Three risk scores were analysed including Framingham,
ASSIGN and QRISK2. We did not analyse the Joint British
Society 2 risk score [3] given the similarity to the Framingham risk
score. The 10-year CVD risks at the index date as predicted by
Framingham and ASSIGN were estimated using the publicly
available risk equations [7,8]. The risks predicted by QRISK2
CVD Risk Prediction
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were calculated using the commercial software program as
provided by CLINRISK Limited on a fee-paying licence using
the 2012 version [http://qrisk.org/index.php]. The CVD risks as
predicted by the risk scores were based on the risk factors
measured at the index date. A previous study reported that lifestyle
variables as recorded in CPRD (such as obesity and smoking) were
important predictors for myocardial infarction [15].
CVD risks based on a competing risk regression model
We also estimated for each patient the individual long-term
CVD risks as modelled by a competing risk Cox proportional
hazards regression model [16]. This was done to estimate as
accurately as possible the actual CVD risks for each patient in the
study population, which could then be compared to the risks as
predicted by the risk scores. Competing risk regression was used as
standard Cox regression model has been reported to overestimate
10-year CVD risk of coronary heart disease [17]. Accounting for
the risks of competing events (such as death due to non-CVD
causes) may be important in the frail and older populations as
CVD occurrence may be precluded by the development of other
diseases. Fractional polynomials were used to model non-linear
risk relations with the continuous variables [18]. The regression
models were conducted separately by gender and three age
groups.
The validation of risk scores involves the measurement of
calibration and discrimination. Calibration is the comparison of
observed and predicted event rates and discrimination the ability
of the risk score to distinguish between people who do and do not
experience the event of interest [19]. We assessed calibration by
comparing observed (using competing risk life tables) and
predicted event rates in subgroups as defined by the vigintiles of
predicted risk (vigintiles are the values that divides the distribution
of individuals into twenty groups of equal frequency). Discrimi-
Table 1. Baseline characteristics of the study population.
Risk factor Men (N=924233) Women (N=927953)
Age at index date Mean (sd) 49.5 (11.3) 50.5 (11.8)
Duration of follow-up after index date Mean (sd) 3.2 (3.0) 3.4 (3.2)
$5 years 221588 (24.0%) 248012 (26.7%)
$10 years 37741 (4.1%) 47159 (5.1%)
Ethnicity White 444617 (48.1%) 538979 (58.1%)
Black 11699 (1.3%) 14820 (1.6%)
Indian 8627 (0.9%) 9805 (1.1%)
Other 17231 (1.9%) 22210 (2.4%)
Unknown 442059 (47.8%) 342139 (36.9%)
Index of deprivation quintiles 1 (most deprived) 230269 (24.9%) 237408 (25.6%)
2 221536 (24.0%) 227396 (24.5%)
3 180771 (19.6%) 182010 (19.6%)
4 170552 (18.5%) 167548 (18.1%)
5 (least deprived) 121105 (13.1%) 113591 (12.2%)
Body mass index Low (,20) 12661 (1.4%) 40105 (4.3%)
Normal ($20 - ,26) 181156 (19.6%) 273038 (29.4%)
Overweight ($26) 249981 (27.0%) 273694 (29.5%)
Unknown 480435 (52.0%) 341116 (36.8%)
Smoking status No 264612 (28.6%) 388477 (41.9%)
Past 120610 (13.0%) 115259 (12.4%)
Current 193165 (20.9%) 171328 (18.5%)
Unknown 345846 (37.4%) 252889 (27.3%)
Systolic blood pressure Recorded 596319 (64.5%) 771566 (83.1%)
Mean (sd) 133.1 (16.3) 128 (18.0)
Cholesterol HDL ratio Recorded 158927 (17.2%) 168611 (18.2%)
Mean (sd) 4.5 (1.4) 3.8 (1.2)
Number of records for medical events in the
electronic health records in the year before
Mean (sd) 10 (14.5) 16.5 (17.6)
Treated hypertension 72459 (7.8%) 91125 (9.8%)
Diabetes mellitus 20144 (2.2%) 15778 (1.7%)
Atrial fibrillation 7247 (0.8%) 4351 (0.5%)
Chronic renal disease 4830 (0.5%) 6998 (0.8%)
Rheumatoid arthritis 4280 (0.5%) 10721 (1.2%)
Left ventricular hypertrophy 2297 (0.2%) 1361 (0.1%)
doi:10.1371/journal.pone.0106455.t001
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nation is the extend a risk score is able to differentiate between
those who develop the outcome and those who do not.
Discrimination is typically assessed by estimating the c index
[19]. Rather than estimating this c index which is a global measure
and population average, we evaluated the predicted risks at the
index date for those people who developed CVD during follow-up.
Good discrimination would have occurred if CVD cases mostly
developed in those with high predicted risks. External validation is
typically recommended for models that need to be generalised to
other populations [19]. Our competing risk regression model was
not intended to be generalised but only to estimate as best as
possible the individual risks in our study population. We also
assessed reclassification by evaluating the consistency in prediction
between the different risk scores.
Descriptive analyses
The main analysis consisted of a comparison of the predictions
of CVD risk at the index date with the four risk scores for each
individual patient. The intraclass correlation coefficients (ICCs) in
individual risk prediction between the four risk scores were
estimated [20]. We report the ICCs rather than Pearson
correlation coefficients because the former provides a measure of
agreement between scores while the latter shows how well one
score predicts the other. This distinction is important when a
threshold (such as 20%) is recommended for deciding the course of
clinical intervention.
Two different analyses were conducted in order to evaluate bias
with the risk scores. The first analysis concerned secular trend in
CVD incidence. CVD incidence has decreased over several
decades [21]. Thus, the risk scores may overestimate CVD risks in
current practice. In order to estimate the potential effects of this
secular trend, incidence rates were measured in each calendar
year. The second bias analysis concerned multiple imputations as
used in the QRISK2 estimation. This method assumes that the
occurrence of missing data is random conditional on other
observed patient characteristics. In UK general practice, risk
factors are typically not recorded unless the patient visits the
practice. People with certain conditions may also be more likely to
be screened for risk factors which incur extra payments (Quality
Outcome Framework). In order to evaluate the effects of
imputation, Cox regression was used to compare the CVD
incidence in people with imputed values (for BMI, systolic blood
pressure, cholesterol and smoking status) and those with measured
values. If the assumption behind multiple imputations is correct, it
can be expected that the CVD rate is similar between those with
recorded and imputed values (conditional on the other risk factors
in the model). SAS version 9.2 was used for the analyses.
Results
The study population included 1.8 million persons with an
average follow-up of 3.3 years (Table 1). Ethnicity was not
recorded for about half of the men and one-third of the women.
About one-quarter of the study population had a follow-up after
the random date of at least 5 years. Women were more likely to
have information on smoking status, BMI and systolic blood
pressure. The extent of missing data decreased sharply over
calendar time. In 1998, BMI was missing in 47.3% of people,
smoking status in 47.3%, systolic blood pressure in 33.4% and
cholesterol/HDL ratio in 97.8%; in 2010, these figures were
32.7%, 14.3%, 22.3% and 72.2%, respectively.
CVD outcomes occurred in 69,870 persons. Major risk factors
for CVD included number of cigarettes smoked per day of 21+
(relative rate [RR]= 2.77 [95% CI 2.54–3.03] in women and
RR=2.45 [95% CI 2.32–2.59] in men), unknown ethnicity
(RR=0.46 [95% CI 0.45–0.48] and RR=0.42 [95% CI 0.42–
0.43]) and 50+ records in CPRD in the year before (RR=5.75
[95% CI 5.33–6.20] and RR=4.31 [95% CI 4.02–4.62]).
The CVD incidence decreased over calendar time. The age-
and sex-adjusted RR of CVD was 0.61 (95% CI 0.59–0.63) in
2010 compared to 1998. This RR was 0.94 (95% CI 0.89–1.00)
for hospitalisations due to CVD (as recorded in HES) and 0.52
(95% CI 0.49–0.54) for GP-recorded CVD. Death due to CVD (as
recorded on death certificates) also decreased over calendar time
(RR of 0.58 [95% CI 0.52–0.64]).
The calibration of the competing risk model showed small
differences on average with observed risks across vigintiles of risk.
The largest difference between predicted and observed CVD risk
occurred in the vigintile with highest risk (predicted 10-year risk of
35.9% compared to an observed risk of 34.9%). The differences
between observed and predicted 10-year risks were on average less
than 0.2% in 16 vigintiles with lowest risk.
Table 2 shows the distribution of 10-year CVD risks as
estimated by competing risk regression. In people aged 50 years
or older, 22.9% had a 10-year CVD risk of $20% and 51.5% of
risk of $10%. The risks varied considerably in this age group: the
5th percentile of 10-year CVD risk was 1.4% and 95th percentile
34.6%.
The level of agreement in CVD risk prediction was best
between ASSIGN and QRISK (intraclass correlation coefficient of
0.93) and lowest between Framingham and estimated risks in
CPRD (0.77). The correlation was 0.91 between Framingham and
ASSIGN, 0.87 between Framingham and QRISK2, 0.80 between
ASSIGN and estimated risks in CPRD and 0.84 between
QRISK2 and estimated risks in CPRD. As shown in Table 3,
the difference in the predicted 10-year CVD risks between
QRISK2 and the risks predicted based a competing risk model
was on average 0.4%, while the predicted 10-year CVD risk with
Framingham was on average 2.3% higher and ASSIGN 1.4%
higher compared to that predicted by the competing risk model.
When analysing the concordance in estimates for individual
persons, only 55.6% of persons had a small difference in the risks
predicted by QRISK2 and the risks based on the competing risk
model.
Table 4 shows the differences between Framingham, ASSIGN
and QRISK2 compared to the estimated risks in CPRD stratified
by the risk factors. The mean differences between QRISK2
predicted risks and estimated risks in CPRD increased by age.
QRISK2 overestimated 10-year CVD risk by 2.2% in people aged
$65 years compared to the risks estimated in CPRD while
QRISK2 predicted and CPRD estimated risks were, on average,
similar in younger people. The concordance between QRISK2
predicted risks and the estimated risks in CPRD changed over
calendar time; QRISK2 underestimated 10-year CVD risk by
3.2% in 1998–2001 and overestimated risk by 2.2% in 2006–2010
compared to the estimated risks in CPRD. Larger deviations
between the risks predicted by QRISK2 and risks estimated in
CPRD occurred with different ethnicities, diabetes mellitus, left
ventricular hypertrophy and number of records for medical events
in the electronic health records in the year before the index date.
The differences in individual risk prediction between the risk
scores were largest among people with higher CVD risks
(Figure 1). In the lowest vigintile of risk, the risk predictions by
QRISK2 were similar to the individual risks estimated in CPRD
(absolute difference of less than 2%) for 99.9% of people; in the
highest vigintile of risk, this was only 13.3%.
The risk scores predicted low 10-year CVD risk fairly
consistently (Table 5). A QRISK2 estimate of low 10-year CVD
CVD Risk Prediction
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risk (,15%) was confirmed by Framingham, ASSIGN and the
CPRD estimated risks in 89.8% of people. An estimate of high 10-
year CVD risk ($20%) by QRISK2 was confirmed in 48.6% of
people.
The majority of CVD cases occurred in people who had a
predicted 10-year CVD risk of less than 20% (Table 6). Only
41.1% of the cases were predicted by QRISK2 to have a 10-year
CVD risk of $20% and 27.5% of the cases a 10-year CVD risk of
less ,10%.
Discussion
We found that all three risk scores (Framingham, ASSIGN and
QRISK2) predicted the presence of low CVD risk consistently in
individual persons. However, predictions of high CVD risk for
individuals varied substantively between the risk scores and
treatment strategies could be different depending on which risk
score is being used. Most CVD cases occurred in people deemed
to be at low CVD risk.
Population averages can hide substantial variability in predic-
tion among individual persons and poor prediction of ‘high risk’
status as these estimates are often determined by the large majority
of low risk individuals. As succinctly stated by Rose, the ability to
estimate the average risk for a group may not be matched by any
corresponding ability to predict which individuals are going to fall
ill soon [11]. The present study confirmed Rose’s observations for
CVD prediction, with a considerable variability between risk
scores in the prediction of high CVD risk and with most CVD
cases occurring in people classified to have lower CVD risk.
The QRISK2 score was developed in a similar setting as the
present study and the statistical methods were also broadly similar.
As expected, we found that the averages of QRISK2 estimates and
our competing risk predictions were reasonably consistent. Two
validation studies of QRISK2 reported that the predicted and
observed risks were on average similar and they concluded that
QRISK2 was accurate in identifying a high risk population
[22,23]. Our analyses of averages support these studies. But we
also conducted analyses of individual risk predictions and reached
opposite conclusions. We found substantial deviations between the
QRISK2 estimates and our competing risk predictions. This was
related to the inclusion into the competing risk models of several
risk factors, as pre-defined in the protocol, which were found to be
strong predictors of risk (such as calendar year, number of GP
visits, region and indicators of missing data including ethnicity).
Our approach, although not commonly used, allows for an
examination of the performance of risk scores in individual persons
rather than testing averages across populations. This regression
approach should provide, as long as the model is specified
correctly, a close representation of the observed risks across
multiple risk factors. The regression models also included risk
factors not used by the published risk scores, such as number of GP
visits (e.g. there was a five-fold difference in CVD risk between
women with frequent and no GP attendance). If the risk scores are
to be used for individual risk prediction, the evaluation of
performance should go beyond population averages.
A recent meta-analysis reported that statins reduced CVD risk
mortality in people with low CVD risk. It concluded that the
threshold for statin treatment should be reduced to a 10-year CVD
risk of 10% [24]. A commentary of this study proposed that statins
should be used by all by the age of 50 years as most people aged 50
years or older have higher risks. It stated, incorrectly, that 83% of
the men older than 50 years and 56% of women older than 60
years have a 10-year CVD risk of $10% [25]. It is questionable
whether whole populations should be treated if individual risks
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vary greatly, as with CVD. Another question is how to deal with
individuals who were not eligible for the trials (e.g. a 50-year old
with normal LDL and C-reactive protein). There is no guarantee
that the treatment effects as observed in trials can be generalised to
populations different from those in the trials [26].
The strength of this study was the large size and representa-
tiveness of the study population, the well-documented data quality
of CPRD [13] and the availability of linked hospital and death
certificate data. There are several important limitations. Informa-
tion on laboratory and physical measurements was missing for a
large number of people. The extent of missing data decreased
substantially over time. Reasons for this decrease include the
availability of electronic communication between practices and
laboratories and the incentivisation of practices in measuring and
recording of data. We applied imputation techniques but found
that people with imputed values had different CVD risks
Figure 1. Absolute differences in individual 10-year CVD risk prediction between the Framingham, ASSIGN and QRISK2 risk scores
and the individual risks estimated in CPRD using competing risk regression stratified by vigintiles of predicted risk. X-axis: Vigintiles
of predicted risk. Y-axis: Percentage of persons.
doi:10.1371/journal.pone.0106455.g001
Table 5. Consistency in risk predictions with risk scores or competing risk regression in predicting high and low CVD risk.
Number of other risk scores
with 10-year CVD risk of $20%
0 1 2 3
Reference risk method $20% % of persons % of persons % of persons % of persons
Framingham risk score 18.2 15.7 24.2 41.9
ASSIGN risk score 4.6 14.2 30.1 51.1
QRISK2 risk score 7.6 15.1 28.6 48.6
Individual risks estimated using
competing risk regression
21.6 15.2 14.5 48.7
Number of other risk scores
with 10-year CVD risk of ,15%
0 1 2 3
,15% % of persons % of persons % of persons % of persons
Framingham risk score 0.6 2.3 3.5 93.5
ASSIGN risk score 0.4 2.2 8.2 89.2
QRISK2 risk score 0.4 2.6 7.3 89.8
Individual risks estimated using
competing risk regression
3.8 3.1 5.9 87.2
doi:10.1371/journal.pone.0106455.t005
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compared to those without missing data. This is not unexpected as
healthy people are less likely to visit their practice. Another
limitation of this study concerned the use of socioeconomic status
in the evaluation of the ASSIGN score. This score used the
Scottish IMD and their values cannot be generalised to other
regions in the UK. Our approach of standardising English to
Scottish IMD may have introduced bias but the direction of bias is
likely to have underestimated differences as socioeconomic status
is, on average, higher in England. The recording of ethnicity in
CPRD also has limitations as there was a substantive discrepancy
in ethnicity between CPRD and HES in the recording of ethnicity.
Another limitation is that the coding by practices of CVD has
changed over calendar time [27] which may explain part of the
trend of lower CVD rates over time. However, a secular trend was
also observed with hospitalisations recorded in HES and death
certificates. The main analyses in this study concerned compar-
isons of predictions by the different risk scores which are not
affected by changes in CVD recording. Another consideration in
this study was the use of a random index date rather than one
based on the start of data collection. This approach reduced
statistical power. However, our rationale for this was the objective
to emulate the performance of risk scores in actual clinical
practice, with assessments being done at arbitrary dates rather
than at the start of data collection. There have also been major
changes in the completeness of data recording over time: an
imputation model that used an index date of 1-1-1998 did not
converge due to high levels of missing cholesterol levels. The
number of people with a follow-up exceeding 10 years was also
larger than that in the studies for ASSIGN, Framingham and
QRISK1 [5,6,8].
In conclusion, the Framingham, ASSIGN and QRISK2 risk
scores do not predict the presence of high CVD risk well and
consistently. Current practice to use any risk score in conjunction
with a constant threshold level has inadvertently created an
arbitrary classification of high CVD risk. Risk prediction strategies
should be based on statistical models that are transparent, derived
from a similar population, with data collected recently and
updated regularly.
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